Evidence map›Paper›PMID 21616678›Full record

ReviewTrends in endocrinology and metabolism: TEM2011

Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance.

Sung Hee Choi, Henry N Ginsberg

Registry-linked trialAbstract readReview
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04395950 (A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor), which is not on this map. Cited by 196 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
196citing papers in PubMed, 2 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04395950 phase1withdrawnnot on this mapstarted 2020, after this paper: background citation

A Phase 1B, Single-Blinded, Linear Two Period, Placebo-controlled Study to Evaluate the Effects of 10 mg/Day of PF-05221304, Liver Targeted Acetyl-CoA Carboxylase Inhibitor (ACCi) on Very Low Density Lipoprotein ApoB100 and TG Secretion

TypeinterventionalSponsorColumbia UniversityRan2020 to 2021Enrolled0ConditionsNASH (Nonalcoholic Steatohepatitis), NAFLD (Nonalcoholic Fatty Liver Disease)ArmsPF-05221304, Placebo
3 · Its place in the literature

Who cites it

196 citing papers in PubMed, 2 syntheses or guidelines pooled it, 390 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review

136 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 2 countries.

Sung Hee ChoiInternal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seoul, Korea.
Henry N Ginsberg
Columbia University · USSeoul National University Bundang Hospital · KR

Funding

Assembly &Secretion Of Apo B Containing LipoproteinsR01HL055638 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 1996 to 2016
$5.9M
Fatty Acid Regulation of Liver Lipoprotein ProductionR01HL073030 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2003 to 2011
$3.6M
NHLBI NIH HHS R01 HL055638NHLBI NIH HHS R01 HL073030
6 · The paper itself

Abstract

Insulin resistance (IR) affects not only the regulation of carbohydrate metabolism but all aspects of lipid and lipoprotein metabolism. IR is associated with increased secretion of VLDL and increased plasma triglycerides, as well as with hepatic steatosis, despite the increased VLDL secretion. Here we link IR with increased VLDL secretion and hepatic steatosis at both the physiologic and molecular levels. Increased VLDL secretion, together with the downstream effects on high density lipoprotein (HDL) cholesterol and low density lipoprotein (LDL) size, is proatherogenic. Hepatic steatosis is a risk factor for steatohepatitis and cirrhosis. Understanding the complex inter-relationships between IR and these abnormalities of liver lipid homeostasis will provide insights relevant to new therapies for these increasing clinical problems.

Indexed as

Fatty LiverHumansInsulin ResistanceLipoproteins, VLDLLipoproteins, VLDL

Identifiers

PMID21616678
PMCPMC3163828
OpenAlexW2011523747

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.